The CEO Roundtable on Cancer has recognized the healthcare business of Merck KGaA, Darmstadt, Germany, operating as EMD Serono in the US and Canada, with the 2020 Charles A. Sanders Award for collaborative scientific research in cancer.

“It is an honor for Merck KGaA, Darmstadt, Germany to be named this year’s recipient of the Charles A. Sanders Life Sciences Award,” said Dr. Belén Garijo, Vice Chair of the Executive Board and Deputy CEO of Merck KGaA, Darmstadt, Germany, CEO Healthcare. “The award is a symbol of our enduring commitment to accelerate the discovery and development of improved treatments for all patients with cancer.”

“Merck KGaA, Darmstadt, Germany, really exemplifies the level and degree of involvement and collaboration that benefits us all,” said Bob Bradway, Chairman of the CEO Roundtable on Cancer and Chairman of Amgen.

Merck KGaA, Darmstadt, Germany, has been a part of the CEO Roundtable on Cancer since 2012 and has earned CEO Cancer Gold Standard accreditation since 2011. The accreditation evaluates health benefits and workplace culture to ensure that companies take extensive, concrete action in five key areas of health and well-being to address cancer in the workplace.

In 2017, Merck KGaA, Darmstadt, Germany, partnered with Project Data Sphere to establish the Global Oncology Big Data Alliance (GOBDA). The purpose of the alliance is to fuel important collaborations in oncology, data science, and regulatory policy. The aim of the alliance is to create new chances to accelerate treatments to oncology patients who need them.

Members of the Merck KGaA, Darmstadt, Germany, team are engaged closely in this work, which is focused on Rare Tumor Registries, Immune Related Adverse Events, and the data-sharing platform operated by Project Data Sphere.